FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159432844> ?p ?o ?g. }

• W3159432844 endingPage "1943" @default.
• W3159432844 startingPage "1931" @default.
• W3159432844 abstract "Considering that the current fixed dose of direct oral anticoagulants (DOACs) might have insufficient anticoagulation effect for overweight patients, the aim of this study was to compare the effectiveness and safety of anticoagulation between dabigatran and rivaroxaban in different body mass index (BMI) population.We conducted a retrospective cohort study of 2402 DOAC anticoagulated patients with atrial fibrillation who underwent catheter ablation (1290 dabigatran, 53.7% and 1112 rivaroxaban, 46.3%) between January 2017 and December 2018. Patients were distributed based on the BMI into nonobese (1362, BMI <25 kg/m2), preobese (521, BMI 25.0-29.9 kg/m2), class I obese (344, BMI 30.0-34.9 kg/m2) and class II+ obese (175, BMI ≥35.0 kg/m2). We collected information regarding clinical features, laboratory data, bleeding complications and systemic embolic events from the electrical medical records system during 12 months.The incidence of systemic embolism and stroke complications was higher in the class II+ obese group (P=0.001 and P=0.003). The incidence of bleeding complications and the levels of anticoagulation parameters under the bleeding threshold were similar among the four groups (P>0.05). Cumulative Kaplan-Meier analysis illustrated that rivaroxaban-treated patients who belonged to higher BMI subgroups were more likely to experience shorter time to thrombosis (TTT) (12-month TTT rates of 0.5% for nonobese vs 1.7% for class I obese patients, HR=3.716, P=0.005; 12-month TTT rates of 0.5%, for nonobese vs 4.0% for class II+ obese patients, HR=6.843, P=0.001). However, no statistical significant difference in terms of the time to bleeding complications and the time to cumulative events among the four groups was observed. By multivariate analysis, a higher BMI value (BMI ≥25 kg/m2) (P=0.019; OR=2.094, 95%CI: 1.129-3.883) was an independent predictor for thrombosis in patients treated with dabigatran or rivaroxaban. Positive linear relationship was observed between BMI levels and occurrence rate of thrombosis and bleeding in under anticoagulation patients with NVAF (R2=0.451 and R2=0.383, respectively).The fixed dose of 15 mg rivaroxaban might carry a risk of under exposure, which would lead to an increase of thromboembolic complications in patients with high BMI. Therefore, rivaroxaban dose increase was suggested for obese patients. Use of DOACs appears to have considerable safety in obese patients." @default.
• W3159432844 created "2021-05-10" @default.
• W3159432844 creator A5013555971 @default.
• W3159432844 creator A5025394309 @default.
• W3159432844 creator A5027091310 @default.
• W3159432844 creator A5027909927 @default.
• W3159432844 creator A5030932372 @default.
• W3159432844 creator A5048369268 @default.
• W3159432844 date "2021-05-01" @default.
• W3159432844 modified "2023-09-25" @default.
• W3159432844 title "Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study" @default.
• W3159432844 cites W1547546593 @default.
• W3159432844 cites W1982653307 @default.
• W3159432844 cites W2044459782 @default.
• W3159432844 cites W2057179512 @default.
• W3159432844 cites W2058710005 @default.
• W3159432844 cites W2074947904 @default.
• W3159432844 cites W2112378432 @default.
• W3159432844 cites W2148024777 @default.
• W3159432844 cites W2156668289 @default.
• W3159432844 cites W2281540926 @default.
• W3159432844 cites W2332141348 @default.
• W3159432844 cites W2337286163 @default.
• W3159432844 cites W2337991204 @default.
• W3159432844 cites W2406927451 @default.
• W3159432844 cites W2509795914 @default.
• W3159432844 cites W2514950920 @default.
• W3159432844 cites W2553524062 @default.
• W3159432844 cites W2603123984 @default.
• W3159432844 cites W2606391344 @default.
• W3159432844 cites W2615293208 @default.
• W3159432844 cites W2623328080 @default.
• W3159432844 cites W2757805356 @default.
• W3159432844 cites W2789744550 @default.
• W3159432844 cites W2790203393 @default.
• W3159432844 cites W2796539606 @default.
• W3159432844 cites W2803831542 @default.
• W3159432844 cites W2888594054 @default.
• W3159432844 cites W2889229861 @default.
• W3159432844 cites W2937581762 @default.
• W3159432844 cites W2957544571 @default.
• W3159432844 cites W2964422565 @default.
• W3159432844 cites W2967644818 @default.
• W3159432844 cites W2982304941 @default.
• W3159432844 cites W2994936956 @default.
• W3159432844 cites W3004050106 @default.
• W3159432844 cites W3014698384 @default.
• W3159432844 cites W3026746774 @default.
• W3159432844 cites W3111031992 @default.
• W3159432844 cites W4242550637 @default.
• W3159432844 cites W4248891350 @default.
• W3159432844 cites W4302435679 @default.
• W3159432844 doi "https://doi.org/10.2147/dddt.s303219" @default.
• W3159432844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8110253" @default.
• W3159432844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33986592" @default.
• W3159432844 hasPublicationYear "2021" @default.
• W3159432844 type Work @default.
• W3159432844 sameAs 3159432844 @default.
• W3159432844 citedByCount "6" @default.
• W3159432844 countsByYear W31594328442022 @default.
• W3159432844 countsByYear W31594328442023 @default.
• W3159432844 crossrefType "journal-article" @default.
• W3159432844 hasAuthorship W3159432844A5013555971 @default.
• W3159432844 hasAuthorship W3159432844A5025394309 @default.
• W3159432844 hasAuthorship W3159432844A5027091310 @default.
• W3159432844 hasAuthorship W3159432844A5027909927 @default.
• W3159432844 hasAuthorship W3159432844A5030932372 @default.
• W3159432844 hasAuthorship W3159432844A5048369268 @default.
• W3159432844 hasBestOaLocation W31594328441 @default.
• W3159432844 hasConcept C120665830 @default.
• W3159432844 hasConcept C121332964 @default.
• W3159432844 hasConcept C126322002 @default.
• W3159432844 hasConcept C127413603 @default.
• W3159432844 hasConcept C141071460 @default.
• W3159432844 hasConcept C167135981 @default.
• W3159432844 hasConcept C195910791 @default.
• W3159432844 hasConcept C2776301958 @default.
• W3159432844 hasConcept C2778661090 @default.
• W3159432844 hasConcept C2778810321 @default.
• W3159432844 hasConcept C2779161974 @default.
• W3159432844 hasConcept C2780221984 @default.
• W3159432844 hasConcept C2780586474 @default.
• W3159432844 hasConcept C2780645631 @default.
• W3159432844 hasConcept C2908647359 @default.
• W3159432844 hasConcept C61511704 @default.
• W3159432844 hasConcept C71924100 @default.
• W3159432844 hasConcept C78519656 @default.
• W3159432844 hasConcept C99454951 @default.
• W3159432844 hasConceptScore W3159432844C120665830 @default.
• W3159432844 hasConceptScore W3159432844C121332964 @default.
• W3159432844 hasConceptScore W3159432844C126322002 @default.
• W3159432844 hasConceptScore W3159432844C127413603 @default.
• W3159432844 hasConceptScore W3159432844C141071460 @default.
• W3159432844 hasConceptScore W3159432844C167135981 @default.
• W3159432844 hasConceptScore W3159432844C195910791 @default.
• W3159432844 hasConceptScore W3159432844C2776301958 @default.
• W3159432844 hasConceptScore W3159432844C2778661090 @default.
• W3159432844 hasConceptScore W3159432844C2778810321 @default.

• next